Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02945579 · ClinicalTrials.gov registry record · NA

Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy

A NA study of Invasive Breast Carcinoma and HER2/Neu Negative, sponsored by M.D. Anderson Cancer Center.

Recruiting
Registry status
NA
Development phase
120
Enrollment target
8
Study locations

NCT02945579 is a NA study of Invasive Breast Carcinoma and HER2/Neu Negative that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 120 participants, below the 482-participant average among 45 other Invasive Breast Carcinoma trials with a reported enrollment target (75% lower). The trial reports 8 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02945579, a NA study of Invasive Breast Carcinoma and HER2/Neu Negative, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.

RECRUITING
Registry status
NA
Development phase
120 participants
Enrollment target
8
Study locations

Study Summary

This clinical trial studies eliminating surgery and/or radiation therapy in treating breast cancer patients. In HER2 positive and triple negative breast cancers, after systemic therapy, when image-guided biopsy shows no residual cancer, patients then receive standard breast radiotherapy with no surgery. In ER positive/HER2 negative breast cancers, after endocrine therapy and ablative radiotherapy, when image-guided biopsy shows no residual cancer, patients then receive standard endocrine therapy with no surgery. For patients who have HER2 positive and triple negative breast cancers and standard surgery, after systemic therapy, breast radiotherapy is being eliminated when the pathology from surgery shows no residual cancer.

Interventions

  • OTHER Quality-of-Life Assessment
  • OTHER Laboratory Biomarker Analysis
  • OTHER Questionnaire Administration
  • RADIATION Undergo EBRT
  • RADIATION Partial Breast Irradiation

Study Locations (8)

Arizona

  • MD Anderson Cancer Center - Banner - Gilbert

Florida

  • Baptist MD Anderson Cancer Center - Jacksonville

Hawaii

  • Queen's Medical Center - Honolulu

Minnesota

  • Mayo Clinic - Rochester

New Jersey

  • Cooper Hospital Univ Med Ctr, MD Anderson at Cooper Voorhees - Voorhees Township

North Carolina

  • Carolinas Medical Center/Levine Cancer Institute - Charlotte

Pennsylvania

  • University of Pittsburgh Cancer Institute (UPCI) - Pittsburgh

Texas

  • M D Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2017-01-20
Est. Completion 2028-01-31
Phase NA

Sponsor

M.D. Anderson Cancer Center

2,692 total trials

What the Registry Record Tells You About NCT02945579

The ClinicalTrials.gov registry entry for NCT02945579 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 482-participant average among 45 other Invasive Breast Carcinoma trials with a reported enrollment target (75% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.

The record links to 10 conditions, with Invasive Breast Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Quality-of-Life Assessment is the first listed.

NCT02945579 reports 8 study locations spanning 8 distinct geographic areas - top geographies include Arizona, Florida, Hawaii.

Frequently Asked Questions

What is clinical trial NCT02945579 about?

NCT02945579 is a clinical study titled "Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy". This clinical trial studies eliminating surgery and/or radiation therapy in treating breast cancer patients. In HER2 positive and triple negative breast cancers, after systemic therapy, when image-guided biopsy shows no residual cancer, patients then receive standard breast radiotherapy with no surg...

What is the current status of trial NCT02945579?

This trial is currently recruiting. It is a NA study. The enrollment target is 120 participants. The study started on 2017-01-20. Estimated completion is 2028-01-31.

What conditions does trial NCT02945579 study?

This clinical trial studies the following conditions: Invasive Breast Carcinoma, HER2/Neu Negative, Estrogen Receptor Negative, Progesterone Receptor Negative, HER2-Positive Breast Carcinoma.

What interventions are being tested in trial NCT02945579?

The interventions under investigation include: Quality-of-Life Assessment (OTHER), Laboratory Biomarker Analysis (OTHER), Questionnaire Administration (OTHER), Undergo EBRT (RADIATION), Partial Breast Irradiation (RADIATION).

Who is sponsoring clinical trial NCT02945579?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02945579 being conducted?

This trial has 8 study locations across Arizona, Florida, Hawaii, Minnesota, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Invasive Breast Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.